Home LiteratureArticle Details
PMID: 8943160 Published · ppublish English Clinical Trial Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease.

The New England journal of medicine ·Vol. 335 ·No. 24 ·1996-12-12 ·Pages 1792-8

Joseph AM, Norman SM, Ferry LH, Prochazka AV, Westman EC, Steele BG, Sherman SE, Cleveland M, Antonuccio DO, Antonnucio DO, Hartman N, McGovern PG

Abstract

Transdermal nicotine therapy is widely used to aid smoking cessation, but there is uncertainty about its safety in patients with cardiac disease. In a randomized, double-blind, placebo-controlled trial at 10 Veterans Affairs medical centers, we randomly assigned 584 outpatients (of whom 576 were men) with at least one diagnosis of cardiovascular disease to a 10-week course of transdermal nicotine or placebo as an aid to smoking cessation. The subjects were monitored for a total of 14 weeks for the primary end points of the study (death, myocardial infarction, cardiac arrest, and admission to the hospital due to increased severity of angina, arrhythmia, or congestive heart failure); the secondary end points (admission to the hospital for other reasons and outpatient visits necessitated by increased severity of heart disease); any side effects of therapy; and abstinence from smoking. There were 48 primary and 78 secondary end points noted in a total of 95 subjects. At least one of the primary end points was reached by 5.4 percent of the subjects in the nicotine group and 7.9 percent of the subjects in the placebo group (difference, 2.5 percent; 95 percent confidence interval, -1.6 to 6.5 percent; P=0.23). In the nicotine group, 11.9 percent of the subjects had at least one of the secondary end points, as compared with 9.7 percent in the placebo group (difference, 2.2 percent; 95 percent confidence interval, -2.2 to 7.4 percent; P= 0.37). After 14 weeks the rate of abstinence from smoking was 21 percent in the nicotine group, as compared with 9 percent in the placebo group (P=0.001), but after 24 weeks the abstinence rates were not significantly different (14 percent vs. 11 percent, P= 0.67). Transdermal nicotine does not cause a significant increase in cardiovascular events in high-risk outpatients with cardiac disease. However, the efficacy of transdermal nicotine as an aid to smoking cessation in such patients is limited and may not be sustained over time.

MeSH Terms
Administration, Cutaneous Aged Aged, 80 and over Analysis of Variance Cardiovascular Diseases Double-Blind Method Female Humans Male Middle Aged Nicotine/adverse effects,therapeutic use Smoking Cessation/methods Treatment Outcome
Chemicals
Nicotine
Authors & Affiliations
12 authors, click to expand affiliations / ORCID
Joseph A M
Department of Medicine, Veterans Affairs (VA) Medical Center and University of Minnesota, Minneapolis 55417, USA.
Norman S M
Ferry L H
Prochazka A V
Westman E C
Steele B G
Sherman S E
Cleveland M
Antonuccio D O
Antonnucio D O
Hartman N
McGovern P G
Article Info
Journal
The New England journal of medicine
Abbr.
N Engl J Med
ISSN
0028-4793
Published
1996-12-12
Pages
1792-8
Language
English
Region
United States
NLM ID
0255562
Subset
IM
Corrections
ErratumIn
-
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]